pi3ka inhibitor compounds, methods for their manufacture and use.

Abstract

This disclosure relates to PI3Ka inhibitors, their crystalline forms, their solvates, and their compositions and methods of use. For example, this disclosure describes compounds in solid form, including crystalline solid forms of the compounds: N-((1S,2R,4S)-4-(((S)-(3-chloro-2,6-difluorophenyl)(4-fluorobicyclo[2.2.1]heptan-1-yl)methyl)carbamoyl)-2-hydroxycyclopentyl)pyrimidine-5-carboxamide; and (1S,3S,4R)-3-acetamido-N-((S)-(3-chloro-2,6-difluorophenyl)(4-fluorobicyclo[2.2.1]heptan-1-yl)methyl)-4-hydroxycyclopentane-1-carboxamide.